.After a handful of years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, using up the best scientific research place at Sanofi.Quigley is going to start Sept. 30 as the French Big Pharma’s chief clinical policeman and also international chief of analysis, Sanofi told Tough Biotech in an emailed statement.Quigley is replacing Frank Nestle, M.D., who left Sanofi this spring amid an international overhaul of the provider’s R&D system. Nestle, who devoted eight years along with the pharma, jumped over to Deerfield Control, where he currently works as a partner on the therapeutics crew as well as chief executive officer of the organization’s restorative revelation as well as growth functions.
Quigley will definitely join Sanofi from a San Francisco-based biotech that resides in secrecy, according to his LinkedIn profile. He’s presently provided as the firm’s co-founder, president as well as chief executive officer.Because August 2021, Quigley has worked as an endeavor partner at SV Wellness Investors, a healthcare fund manager with existing financial investments in biotechs like BioAge, Cerevance, Dualitas Rehabs and Nimbus Rehabs, to name a few. Quigley previously held the best spot at Dualitas, a biotech that remains in secrecy, depending on to STAT.The future Sanofi leader additionally formerly helmed Therini Biography, an immunotherapy biotech operating to develop procedures for neurodegenerative diseases steered through vascular dysfunction.Just before investing the last handful of years in biotech, Quigley has an even longer record in Major Pharma, very most just recently functioning as Gilead’s elderly bad habit head of state of investigation the field of biology until the summertime of 2021.
Prior to that, he appeared more than 4 years across various leadership duties at Bristol Myers Squibb and acted as a medical director at Johnson & Johnson’s Janssen arm prior to that.Sanofi pointed out Quigley’s mission in his new job will be actually to “optimize our likelihood of effectiveness via optimal collaborations across our company as well as past, bringing best-in-class technology along with establishing and sourcing new industry-leading ability along with a commitment to range,” depending on to an interior memorandum gotten through STAT.